PharmiWeb.com - Global Pharma News & Resources
23-Nov-2023

Asklepios Group: Sound business performance in first nine months of 2023

EQS-News: Asklepios Kliniken / Key word(s): 9 Month figures/Financing
Asklepios Group: Sound business performance in first nine months of 2023
23.11.2023 / 10:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

Asklepios Group: Sound business performance in first nine months of 2023

  • Revenue improves to EUR 4,077.7 million
  • Inflation-driven price increases and higher staff costs affect consolidated net income
  • Syndicated loan increased by EUR 200.0 million

Hamburg, 23 November 2023. Asklepios Kliniken GmbH & Co. KGaA recorded sound business performance in the first nine months of 2023. Important aspects of the hospital reform, such as hospital funding and combating the shortage of specialist staff, have not yet been clarified. Consolidated net income was negatively impacted by higher material and staff costs.

As in the previous year, a total of 2.6 million patients were treated at the Asklepios Group’s healthcare facilities in the first nine months of the current financial year. The number of full-time equivalents also remained unchanged as against the previous year at around 50,000.

Asklepios generated year-on-year revenue growth of 3.6% to EUR 4,077.7 million (9M 2022: EUR 3,935.4 million). Staff costs climbed by EUR 156.1 million or 6.0% year-on-year to EUR 2,739.0 million due to general collective wage increases, with the staff costs ratio rising from 65.6% to 67.2% as a result.

Inflation-driven price increases led to higher purchasing costs for food and medical supplies. Compared to the previous year, the cost of materials rose by 4.1% to EUR 993.0 million. The cost of materials ratio increased to 24.4% after the first nine months of the year (9M 2022: 24.2%).

The overall increase in expenses had an impact on consolidated net income (EAT), which declined year-on-year to EUR 81.9 million after the first nine months of 2023 (9M 2022: EUR 104.9 million). The EAT margin was also lower at 2.0% (9M 2022: 2.7%).

“Asklepios has achieved sound business performance despite the challenging environment. Unfortunately, there are currently no signs of a sustainable improvement in the conditions for hospitals in Germany. Although the urgently needed hospital reform presents a major opportunity, its implementation does not seem conducive to the provision of modern, future-proof healthcare,” says Kai Hankeln, CEO of Asklepios Kliniken.

Hafid Rifi, CFO of Asklepios Kliniken: “In a generally volatile market environment, the situation in many German hospitals is getting worse. Securing hospitals’ liquidity is a top priority for Asklepios, as these hospitals are indispensable for people in rural areas in particular. The challenges of the unsettled market necessitate forward-looking financial planning with a strategic mindset in order to ensure the future viability of our facilities.”

To expand its strategic liquidity reserve, Asklepios has increased the syndicated loan that was concluded with a syndicate of eleven banks on 12 August 2021, which has a residual term until 2028 following the successful exercise of both renewal options, by a further EUR 200.0 million to a total volume of EUR 750.0 million.

Despite the uncertain market environment, Asklepios Kliniken is aiming for a sustainable overall improvement in operating earnings in 2023 as a whole.

About Asklepios
Asklepios Kliniken is one of the leading private operators of hospitals and healthcare facilities in Germany. The hospital group stands for highly qualified care for its patients, with a clear commitment to medical quality, innovation and social responsibility. On this basis, Asklepios has been developing dynamically since it was founded over 35 years ago. The Group currently has around 170 healthcare facilities throughout Germany. These include acute care hospitals of all different care levels, university hospitals, specialist clinics, psychiatric facilities, forensic institutions, rehabilitation clinics, nursing homes and medical centres. In the 2022 financial year, around 3.6 million patients were treated at the Asklepios Group’s facilities. The company has more than 67,000 employees.

IR contact
Mirjam Constantin
Head of Group ESG & Sustainability/ Manager Investor Relations
Asklepios Kliniken GmbH & Co. KGaA
Debusweg 3 - 61462 Königstein-Falkenstein
Tel.: +49 61 74 90-1166
Fax: +49 61 74 90-1110
ir@asklepios.com

PR contact
Rune Hoffmann
Head of Corporate Communications & Marketing
Asklepios Kliniken GmbH & Co. KGaA
Rübenkamp 226 - 22307 Hamburg
Tel.: +49 40 1818-82 6630
Fax: +49 40 1818-82 6639
presse@asklepios.com

Visit Asklepios online, on Facebook or on YouTube:
www.asklepios.com
gesundleben.asklepios.com
www.facebook.com/asklepioskliniken
www.youtube.com/asklepioskliniken



23.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Editor Details

Last Updated: 23-Nov-2023